ctDNA-Guided Pembrolizumab Clears Minimal Residual Disease in Resected dMMR Solid Tumors in Phase 2 Trial.

A phase 2 clinical trial investigated the use of circulating tumor DNA (ctDNA) to guide treatment decisions following surgery for patients with resected mismatch repair-deficient (dMMR) solid tumors. The study showed that this approach, using ctDNA to determine if patients received adjuvant pembrolizumab, effectively cleared minimal residual disease and reduced the recurrence of cancer. Specifically, the trial involved patients who had undergone surgery for dMMR solid tumors. Researchers used ctDNA analysis to detect minimal residual disease. If ctDNA was detected, indicating the presence of remaining cancer cells, patients received adjuvant pembrolizumab, an immunotherapy drug, after surgery. The trial results indicated that this strategy led to the elimination of minimal residual disease and a decrease in the recurrence of the cancer.

Newsflash | Powered by GeneOnline AI
Date: April 28, 2025

Related posts:

Social Media Engagement Boosts Product Purchases by 25%: Study Reveals Impact on Consumer Behavior Biotech Update: Phase 2 Trial Shows Statistically Significant Improvement for New Drug Candidate New Software Interface Boosts Task Completion by 15% Francis Collins Cites Canceled NIH Grants and HHS Layoffs as Threat to U.S. Biomedical Leadership

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後